PDF(Pubmed)
Abstract：
UNASSIGNED: Since 2018, British Columbia (BC) has recommended chronic hepatitis C (HCV) screening for those born between 1945 and 1964, with a provincial prevalence of 2.31%. Combining HCV and colorectal cancer (CRC) screening can facilitate specialist referrals and follow-up. We assessed HCV screening uptake among CRC screening patients following the release of BC\'s birth cohort guidelines and examined the COVID-19 pandemic\'s impact on HCV screening practices.
UNASSIGNED: A retrospective review was conducted on patients referred to Vancouver Coastal Health Authority\'s CRC screening program. Two groups, Cohort A (October-December 2019) and Cohort B (December 2021), were studied to identify pandemic-related changes. Data on demographics, liver disease history, hepatitis B or HIV co-infection rates, and initial anti-hepatitis C and ribonucleic acid (RNA) testing dates were collected. Statistical analyses were performed with Stata 15.1.
UNASSIGNED: A total of 579 patients were referred for the CRC screening program, of whom 465 were born between 1945 and 1964 and were included in the study. Among the 348 patients in cohort A, 144 (41%, 95% CI 36%-47%) were screened for HCV infection. Of these, four (1.2%) were positive for anti-hepatitis C, and one patient had positive RNA levels. Similar proportions of screenings were observed in cohort B (47.8%, 95% CI 39%-57%). Of those with liver disease, 66% had been screened for HCV.
UNASSIGNED: Birth cohort screening for HCV has been underutilized in British Columbia. Combining HCV and CRC screening could provide a practical approach to linking patients to health care.
UNASSIGNED: A retrospective review was conducted on patients referred to Vancouver Coastal Health Authority\'s CRC screening program. Two groups, Cohort A (October-December 2019) and Cohort B (December 2021), were studied to identify pandemic-related changes. Data on demographics, liver disease history, hepatitis B or HIV co-infection rates, and initial anti-hepatitis C and ribonucleic acid (RNA) testing dates were collected. Statistical analyses were performed with Stata 15.1.
UNASSIGNED: A total of 579 patients were referred for the CRC screening program, of whom 465 were born between 1945 and 1964 and were included in the study. Among the 348 patients in cohort A, 144 (41%, 95% CI 36%-47%) were screened for HCV infection. Of these, four (1.2%) were positive for anti-hepatitis C, and one patient had positive RNA levels. Similar proportions of screenings were observed in cohort B (47.8%, 95% CI 39%-57%). Of those with liver disease, 66% had been screened for HCV.
UNASSIGNED: Birth cohort screening for HCV has been underutilized in British Columbia. Combining HCV and CRC screening could provide a practical approach to linking patients to health care.
摘要：
■自2018年以来，不列颠哥伦比亚省（BC）建议对1945年至1964年之间出生的人进行慢性丙型肝炎（HCV）筛查，省级患病率为2.31％。结合HCV和结直肠癌（CRC）筛查可以促进专家转诊和随访。在BC的出生队列指南发布后，我们评估了CRC筛查患者的HCV筛查摄入量，并检查了COVID-19大流行对HCV筛查实践的影响。
■对温哥华沿海卫生局CRC筛查计划的患者进行了回顾性审查。两组,队列A（2019年10月至12月）和队列B（2021年12月），进行了研究，以确定与大流行相关的变化。人口统计数据，肝病史,乙型肝炎或艾滋病毒合并感染率，收集初始抗丙型肝炎和核糖核酸（RNA）检测日期。用Stata15.1进行统计分析。
■共有579名患者被转诊为CRC筛查计划，其中465人出生在1945年至1964年之间，并被纳入研究。在队列A的348名患者中，144（41%，95%CI36%-47%)进行HCV感染筛查。其中,4例（1.2%）抗丙型肝炎阳性，一名患者的RNA水平呈阳性。在队列B中观察到相似的筛查比例(47.8%，95%CI39%-57%）。在患有肝病的人中，66%的人接受了HCV筛查。
■在不列颠哥伦比亚省，HCV的出生队列筛查未得到充分利用。结合HCV和CRC筛查可以提供一种将患者与医疗保健联系起来的实用方法。
■对温哥华沿海卫生局CRC筛查计划的患者进行了回顾性审查。两组,队列A（2019年10月至12月）和队列B（2021年12月），进行了研究，以确定与大流行相关的变化。人口统计数据，肝病史,乙型肝炎或艾滋病毒合并感染率，收集初始抗丙型肝炎和核糖核酸（RNA）检测日期。用Stata15.1进行统计分析。
■共有579名患者被转诊为CRC筛查计划，其中465人出生在1945年至1964年之间，并被纳入研究。在队列A的348名患者中，144（41%，95%CI36%-47%)进行HCV感染筛查。其中,4例（1.2%）抗丙型肝炎阳性，一名患者的RNA水平呈阳性。在队列B中观察到相似的筛查比例(47.8%，95%CI39%-57%）。在患有肝病的人中，66%的人接受了HCV筛查。
■在不列颠哥伦比亚省，HCV的出生队列筛查未得到充分利用。结合HCV和CRC筛查可以提供一种将患者与医疗保健联系起来的实用方法。
